Abeona Therapeutics faces securities fraud probe after Q2 revenue recognition issues hit stock price.

Pomerantz LLP is investigating Abeona Therapeutics for potential securities fraud following the company's Q2 2026 financial report. Abeona disclosed that only four out of five patient treatments were recognized for revenue due to one batch not meeting requirements, causing the stock to drop nearly 15%. The investigation will determine if Abeona and its executives engaged in unlawful business practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP for possible class action participation.